IL-36 signalling as a therapeutic target in pustular psoriasis
Lead Research Organisation:
King's College London
Department Name: Genetics and Molecular Medicine
Abstract
The aim of this study is to characterise the immune responses driven by interleukin-(IL) 36, an inflammatory molecule that is currently being targeted for the treatment of pustular psoriasis. We specifically propose to combine our expertise in basic science (Capon), clinical dermatology (Smith) and drug development (Boehringer-Ingelheim), to achieve the following objectives:
I: Identifying the immune cell types that are sensitive to IL-36.
II: Dissecting the effects of abnormal IL-36 activity.
III: Determining whether the effects of pustular psoriasis mutations can be reversed by IL-36 blockade.
I: Identifying the immune cell types that are sensitive to IL-36.
II: Dissecting the effects of abnormal IL-36 activity.
III: Determining whether the effects of pustular psoriasis mutations can be reversed by IL-36 blockade.
People |
ORCID iD |
Catherine Smith (Primary Supervisor) | |
Daniel McCluskey (Student) |
Studentship Projects
Project Reference | Relationship | Related To | Start | End | Student Name |
---|---|---|---|---|---|
MR/R015643/1 | 01/10/2018 | 30/09/2025 | |||
2072060 | Studentship | MR/R015643/1 | 01/10/2018 | 30/03/2022 | Daniel McCluskey |